Akebia Therapeutics (AKBA)
(Real Time Quote from BATS)
$1.33 USD
-0.04 (-2.92%)
Updated Apr 25, 2024 01:26 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKBA 1.33 -0.04(-2.92%)
Will AKBA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
Other News for AKBA
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Wall Street Analysts Are Bullish on Top Healthcare Picks